1. Home
  2. REGN vs MDLZ Comparison

REGN vs MDLZ Comparison

Compare REGN & MDLZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • MDLZ
  • Stock Information
  • Founded
  • REGN 1988
  • MDLZ 2000
  • Country
  • REGN United States
  • MDLZ United States
  • Employees
  • REGN N/A
  • MDLZ N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • MDLZ Packaged Foods
  • Sector
  • REGN Health Care
  • MDLZ Consumer Staples
  • Exchange
  • REGN Nasdaq
  • MDLZ Nasdaq
  • Market Cap
  • REGN 110.0B
  • MDLZ 99.1B
  • IPO Year
  • REGN 1991
  • MDLZ N/A
  • Fundamental
  • Price
  • REGN $743.35
  • MDLZ $64.42
  • Analyst Decision
  • REGN Buy
  • MDLZ Strong Buy
  • Analyst Count
  • REGN 24
  • MDLZ 17
  • Target Price
  • REGN $1,110.63
  • MDLZ $80.76
  • AVG Volume (30 Days)
  • REGN 837.3K
  • MDLZ 6.5M
  • Earning Date
  • REGN 10-31-2024
  • MDLZ 10-29-2024
  • Dividend Yield
  • REGN N/A
  • MDLZ 2.93%
  • EPS Growth
  • REGN 15.31
  • MDLZ N/A
  • EPS
  • REGN 40.43
  • MDLZ 2.82
  • Revenue
  • REGN $13,847,100,000.00
  • MDLZ $36,151,000,000.00
  • Revenue This Year
  • REGN $10.13
  • MDLZ $3.61
  • Revenue Next Year
  • REGN $4.00
  • MDLZ $4.40
  • P/E Ratio
  • REGN $18.39
  • MDLZ $22.85
  • Revenue Growth
  • REGN 5.72
  • MDLZ 2.13
  • 52 Week Low
  • REGN $736.01
  • MDLZ $63.40
  • 52 Week High
  • REGN $1,211.20
  • MDLZ $77.20
  • Technical
  • Relative Strength Index (RSI)
  • REGN 13.08
  • MDLZ 29.83
  • Support Level
  • REGN $813.53
  • MDLZ $63.40
  • Resistance Level
  • REGN $834.42
  • MDLZ $66.41
  • Average True Range (ATR)
  • REGN 19.56
  • MDLZ 1.09
  • MACD
  • REGN -3.19
  • MDLZ -0.21
  • Stochastic Oscillator
  • REGN 5.83
  • MDLZ 17.62

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

About MDLZ Mondelez International Inc.

Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales), chocolate (30%), gum/candy (12%), beverage (3%), and cheese and grocery (6%) aisles, as of the end of fiscal 2023. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury, among others. The firm derives around one third of revenue from developing markets, just more than one third from Europe, and the remainder from North America.

Share on Social Networks: